All Articles
The CDK4/CDK6 inhibitor Verzenio received a new indication, for use alone or in combination with an aromatase inhibitor, as initial therapy in women with HR-positive, HER2-negative advanced or metastatic breast cancer. Read More ›
This is the first time the FDA has used minimal residual disease (MRD) as a biomarker to approve a specific treatment for patients with acute lymphoblastic leukemia (ALL). Read More ›
A national advocacy program trains patients with metastatic breast cancer to educate the public about the special needs of patients with advanced breast cancer. Read More ›
Dr Hayes, Immediate Past President of ASCO and Professor of Breast Cancer Research at the University of Michigan Comprehensive Cancer Center, explains how biomarkers offer more precise treatment opportunities for patients with breast cancer. Read More ›
By Laura Morgan
The terms genetics and genomics are often used interchangeably in relation to cancer, but they refer to different things and are becoming very important in cancer treatment. Read More ›
By Dana Taylor
Read about important advancements in tumor biomarkers and their role in guiding treatment in some types of cancer. Read More ›